PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.

NDAQ:SGMO) Investors who lost money on Sangamo Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - SGMO ...

Sangamo Therapeutics SGMO stock crashed 60.4% after hours on Monday after it announced that its partner, Pfizer PFE, ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...

Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC ...

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an ...

Sangamo (SGMO) stock faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price ...

Law Offices of Howard G. Smith announces an investigation on behalf of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) investor ...

Sangamo Therapeutics Inc (SGMO) stock saw a decline, ending the day at $1.02 which represents a decrease of $-1.32 or -56.41% from the prior close of $2.34. The stock opened at $1.07 and touched a low ...

9 analysts have shared their evaluations of Sangamo Therapeutics SGMO during the recent three months, expressing a mix of ...

Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...